PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109413
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109413
The North America stem cell therapy market is projected to register a substantial CAGR of 8.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
North America Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada) Industry Trends and Forecast to 2029.
The rise in the incidence of chronic diseases in the U.S.
Growth in research and development
Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew)
Orthofix Medical Inc.
Takeda Pharmaceutical Company Limited
U.S. Stem Cell, Inc.
BrainStorm Cell Limited
International Stemcell Corporation
Athersys, Inc.
BioRestorative Therapies, Inc.
JCR Pharmaceuticals Co., Ltd
ANTEROGEN.CO., LTD
MEDIPOST
Mesoblast Ltd
PHARMICELL Co., Ltd.
STEMPEUTICS RESEARCH PVT LTD